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Abstract
Myc, a pleiotropic transcription factor that is deregulated and/or overexpressed in most human cancers, instructs
multiple extracellular programs that are required to sustain the complex microenvironment needed for tumor main-
tenance, including remodeling of tumor stroma, angiogenesis, and inflammation. We previously showed in a
model of pancreatic β-cell tumorigenesis that acute Myc activation in vivo triggers rapid recruitment of mast cells
to the tumor site and that this is absolutely required for angiogenesis and macroscopic tumor expansion. More-
over, systemic inhibition of mast cell degranulation with sodium cromoglycate induced death of tumor and endo-
thelial cells in established tumors. Hence, mast cells are required both to establish and to maintain the tumors.
Whereas this intimates that selective inhibition of mast cell function could be therapeutically efficacious, cromo-
glycate is not a practical drug for systemic delivery in humans, and no other systemic inhibitor of mast cell degran-
ulation has hitherto been available. PCI-32765 is a novel inhibitor of Bruton tyrosine kinase (Btk) that blocks mast
cell degranulation and is currently in clinical trial as a therapy for B-cell non–Hodgkin lymphoma. Here, we show
that systemic treatment of insulinoma-bearing mice with PCI-32765 efficiently inhibits Btk, blocks mast cell degran-
ulation, and triggers collapse of tumor vasculature and tumor regression. These data reinforce the notion that mast
cell function is required for maintenance of certain tumor types and indicate that the Btk inhibitor PCI-32765 may
be useful in treating such diseases.
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Introduction
Many chronic diseases are associated with an aberrant inflammatory
response (reviewed in Porta et al. [1]), although in the case of cancer,
there is still debate as to whether inflammation is primarily a cause
or a consequence of the pathological state. The simple notion that
inflammation reflects a host defensive response to the tumor within
its midst is consistent with reports that inflammation can be protec-
tive against certain cancers (for a review, see Grivennikov et al. [2]).
However, this simple immune surveillance idea, although applicable in
some instances, has been qualified by recent studies that indicate that
“inflammation” is frequently a collateral consequence of the extensive
tissue remodeling that tumor cells instruct within their immediate
somatic microenvironment—remodeling that is mediated through
the actions of heterotypic inflammatory cells such as macrophages,
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neutrophils, lymphocytes, and mast cells [3]. In this sense, inflamma-
tion is an integral part of the macroscopic tumorigenic process. Consis-
tent with this idea, many studies have demonstrated that expansion and
maintenance of macroscopic tumors is continuously dependent on the
actions of inflammatory cells.
Using the well-described model of Myc-driven pancreatic insulinoma
Tg(Ins-MYC/Er)1Gev;Tg(Ins-BCL2L1)2Ksp (designated henceforth
Ins-MycERTAM;RIP7-Bcl-xL) [4,5], we previously demonstrated that
activation of Myc in the β-cell compartment is, alone, sufficient to ini-
tiate and orchestrate a complex inflammatory and angiogenic response,
characterized by the expeditious induction of a chemokine-encoding
gene cluster and interleukin 1β [6,7], which trigger influx of mast cells,
macrophages, and neutrophils into the tumors and their immediate
milieu. Most notably, mast cells are rapidly recruited into the mesen-
chyme adjacent to islets, and the onset of islet angiogenesis and tumor
expansion are observed immediately thereafter [7]. By a combined
genetic and pharmacological approach, we further demonstrated that
mast cell recruitment is absolutely required for tumor angiogenesis
and macroscopic β-cell tumor expansion; moreover, systemic treatment
of mice harboring established β-cell tumors with a mast cell inhibitor
(sodium cromoglycate) triggered rapid onset of hypoxia and death of
tumor and endothelial cells [7]. Whereas sodium cromoglycate is a very
poor systemic drug with low bioavailability, our observations indicated
that more systemically effective inhibitors of mast cell function might
be therapeutically useful in treating pancreatic insulinoma and, possi-
bly, other tumors. PCI-32765 is a novel, potent, and selective inhibitor
of Bruton tyrosine kinase (Btk) already in clinical trials for B-cell non–
Hodgkin lymphoma [8,9]. Btk is required for B-cell receptor signaling
but is also critical for mast cell degranulation, acting downstream of the
high-affinity IgE receptor (FcɛRI) [10]. Indeed, Btk-deficient mice
exhibit impaired degranulation after FcɛRI cross-linking [11]. Here,
we use PCI-32765 in an experimental model of pancreatic insulinoma
to test the notion that inhibition of mast cell degranulation is a feasible
therapeutic approach.
Materials and Methods
Generation and Maintenance of Mice
Tg(Ins-MYC/Er)1Gev;Tg(Ins-BCL2L1)2Ksp mice were generated as
described in Pelengaris et al. [4]. Jh Targeted Mutation Mice (Taconic,
Hudson, NY) were a generous gift from Lisa Coussens. MycERTAM
was activated in pancreatic islets by daily intraperitoneal (i.p.) injection
of 1 mg of tamoxifen dissolved in peanut oil vehicle. PCI-32765 was
administered either daily by i.p. injection (5 mg/kg) dissolved in saline
or in drinking water (0.16 mg/ml in 1% HP-beta-CD). Mice were
housed and treated in accordance with protocols approved by the
Institutional Animal Care and Use Committee at the University of
California, San Francisco. At least five mice were present in each experi-
mental cohort with the exception of the glucose tolerance assay, where
cohorts comprised three mice.
Hexaminidase Release Assay
RBL-2H3 cells were obtained from ATCC, Manassas, VA in
December 2007 (ATCC CRL-2256). The cell line was authenticated
at ATCC according to the company’s standard procedures (including cell
morphology, karyotyping, and cytochrome C oxidase I testing). After a
single passage, the aliquots of the cells were frozen in liquid N2 and then
thawed in 2010 for the experiments used in this paper. Cells were
plated at 5 × 105 cells/ml in minimum essential medium + 10% fetal
calf serum in black-walled 96-well plates. Twenty-four hours later,
anti–DNP-BSA IgE (Calbiochem, Billerica, MA) was added to 1 μg/ml
followed by increasing doses (0.01-3 μM) of PCI-32765. Cells were in-
cubated for 1 hour and then washed three times in degranulation buffer
(as described in Sainte-Laudy et al. [12]). Degranulation was then induced
by cross-linking with DNP-BSA for 1 hour. Hexaminidase released into
cytosol or culture medium was quantitated using a fluorescent substrate
cleavage hexosaminidase assay. No cytotoxicity (Alamar Blue assay) was
evident after PCI-32765 treatment alone. Each experiment was run in
duplicate and repeated at least three times with similar results.
Tissue Preparation and Histology
Mice were killed and cardiac perfused with phosphate-buffered
saline (PBS) followed by zinc-buffered formalin. Pancreata were removed
and either frozen in OCT or fixed overnight in zinc-buffered formalin
and processed for paraffin embedding. For histologic analysis, tissue
sections (5 μm) were stained with hematoxylin and eosin.
Immunohistochemistry
For immunohistochemical analysis, sections were deparaffinized,
rehydrated, and subjected to high-temperature antigen retrieval in
10 mM citrate buffer (pH 6.0). The primary antibodies used were
as follows: rabbit monoclonal anti-Ki67 (clone SP6) (Lab Vision,
Fremont, CA), rat monoclonal anti-MECA32 (BD PharMingen,
San Diego, CA), polyclonal guinea pig anti human insulin antibody
(Biogenex, Fremont, CA), mouse monoclonal anti–human chromo-
granin A (clone 5H7; DAKO, Carpinteria, CA), and rabbit polyclonal
anti–human c-Kit (DAKO). These primary antibodies were applied for
2 hours in blocking buffer (2.5% BSA, 5% goat serum, 0.3% Triton
X-100 in PBS), followed by species-appropriate secondary Alexa Fluor
488 dye–conjugated antibodies (Amersham, Piscataway, NJ) or Vectastain
ABC kit and DAB reagents (Vector Laboratories, Burlingame, CA).
Fluorescence antibody–labeled slides were mounted in DAKO fluores-
cent mounting medium containing 1 μg/ml Hoechst counterstain. HRP-
conjugated secondary antibodies were visualized by DAB staining (Vector
Laboratories). Apoptotic cells were detected with ApopTag Detection
kit (Chemicon International, Billerica, MA). Images were obtained
with an Axiovert S100 TV inverted fluorescence microscope (Zeiss,
Figure 1. PCI-32765 inhibits mast cell degranulation. In vitro quantita-
tion of mast cell degranulation by hexaminidase release assay. Rat
RBL-2H3 mast cells were incubated with PCI-32765 and degranula-
tion then triggered by IgE receptor cross-linking. The extent of degran-
ulation was quantitated by assaying release of hexosaminidase.
Numbers represent means of duplicate measurements.
1094 Btk Inhibition in Insulinoma Soucek et al. Neoplasia Vol. 13, No. 11, 2011
Thornwood, NY) and Open Lab 3.5.1 software or with an Axiovert
100 inverted microscope (Zeiss) equipped with a Hamamatsu Orca
digital camera (Bridgewater, NJ). At least 12 islets were analyzed for
each experimental condition.
To quantitate islet size, pancreata from five mice per cohort were
analyzed, and at least 12 islets per mouse were measured. For prolif-
eration and apoptosis quantification, six islets per mouse and five
mice per cohort were analyzed.
Glucose Tolerance Assay
Mice were fasted for 24 hours of fasting and then challenged with an
i.p. bolus of glucose (10 μl/g of 1-M stock solution), and their blood glu-
cose levels were then determined every 20 minutes for a further 2 hours.
Btk Occupancy Assay
For analysis of Btk occupancy after oral dosing of PCI-32765,
spleens were disaggregated into isolated splenocytes, which were then
Figure 2. Short-term (1 week) treatment with PCI-32765 induces death of both tumor and adjacent endothelial cells. (A) Hematoxylin and
eosin (H&E) staining of pancreata harvested from Ins-MycERTAM;RIP7-Bcl-xL mice treated with PCI-32765 only (left panel), with tamoxifen
only (middle panel), or with both tamoxifen and PCI-32765 (right panel). (B) TUNEL staining of sections described above. TUNEL-positive
apoptotic cells are indicated by black circles. (C) Meca32 (red) and TUNEL (green) double staining showing the presence of dying endo-
thelial cells in tumors treated with PCI-32765. Hoechst nuclear counterstaining (blue) is shown in the left panels. i, ii, iii, and iv indicate
higher magnification of TUNEL-positive apoptotic endothelial cells.
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incubated for 5 minutes in red blood cell–lysing buffer (Sigma-
Aldrich, St Louis, MO). Cells were then treated with PCI-33380,
and lysates were analyzed as described in Honigberg et al. [8].
Results
Systemic PCI-32765 Efficiently Inhibits Mast
Cell Degranulation
PCI-32765 has previously been shown to bind covalently to, and to
be selective for, Cys481 in the Btk active site, inhibiting its enzymatic
activity [8,9]. To assess the capacity of PCI-32765 to suppress murine
mast cell function in vitro, we used rat RBL-2H3 cells, which are estab-
lished analogs of rat mucosal mast cells. RBL-2H3 cell surface IgE
receptors were cross-linked in the absence or presence of increasing
amounts (0.01-3 μM) of PCI-32765 and the impact on degranulation
assayed by the release of the granule-derived enzyme hexosaminidase in
cells and culture supernatants (Figure 1). PCI-32765 efficiently inhib-
ited hexosaminidase release, indicating efficacious blockade of mast
cell degranulation.
PCI-32765 Blocks Expansion of Myc-Driven Insulinomas
To exclude a possible role of B cells in our insulinoma model that
would confound interpretation of any potential PCI-32765 effect,
we used JH gene-deficient mice that lack mature B lymphocytes
[13] and crossed them into our Ins-MycERTAM;RIP7-Bcl-xL model.
Myc was then activated in the pancreatic β cells by daily injection
of tamoxifen for 2 weeks to elicit tumorigenesis. Such sustained
Myc activation drives progressive and synchronous tumorigenic
expansion of the β-cell compartment, accompanied by remodeling
of the tumor stroma and proliferation of the endothelial compart-
ment, resulting in multifocal insulinoma [4,6,7]. Even in the com-
plete absence of B-cell function, Myc activation led to expansion of
the islets into insulinomas (Figure W1), excluding B-cell requirement
for β-cell tumorigenesis, allowing us to focus on other potential tar-
gets of PCI-32765.
To assess the impact of PCI-32765 on insulinoma growth, we
treated Ins-MycERTAM;RIP7-Bcl-xL mice for 2 weeks with tamoxifen.
At this point, when all the mice presented overt and angiogenic β-cell
tumors, either 5 mg/kg PCI-32765 or control vehicle was administered
for a further 7 days, together with daily tamoxifen to maintain Myc
activity. Mice were then sacrificed, and pancreata were harvested for
immunohistochemical analysis. At this stage, as a consequence of
Myc activation, in each section, we observed an average 4.6 ± 0.4-fold
increase in the islet area over controls. However, in animals treated with
PCI-32765, the increase was reduced to 1.84 ± 0.35 (Figure 2A). This
difference in tumor size coincided with the appearance of apoptotic
(positive for terminal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL)) cells within each tumor mass (3.2% ± 1.1%), whereas no
apoptotic cells were evident in the vehicle-treated controls (Figure 2B).
Of note, however, almost half (48.7% ± 5.1%) of the apoptotic cells were
not β endocrine but endothelial, as evidenced by double staining for the
endothelial cell marker Meca32 (Figure 2C). These data are consistent
with our previous studies showing that inhibition of mast cell degranu-
lation rapidly triggers collapse of tumor vasculature, tumor hypoxia, and
regression [7]. Intriguingly, PCI-32765 treatment also induced a significant
Figure 3. PCI-32765 inhibits the proliferation of tumor cells. Ki67 (proliferative marker) staining of sections of pancreata harvested from
Ins-MycERTAM;RIP7-Bcl-xL mice treated with PCI-32765 only (left panel), with tamoxifen only (middle panel), or both (right panel). Lower
inserts show higher-magnification images of Ki67-positive cells. Quantification of Ki67-positive cells is also provided for of each geno-
type and treatment condition.
Figure 4. PCI-32765 does not compromise glucose tolerance.
Mice previously subjected to 24-hour fasting were challenged by
i.p. injection of a bolus of glucose (10 μl/g of 1 M stock solution),
and their blood glucose levels were measured every 20 minutes
during the ensuing 2 hours. Continuous lines represent mice pre-
treated for 3 days with PCI-32765, whereas broken lines depict
vehicle-treated controls.
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reduction in the proportion of proliferating tumor cells (9.6% ± 4.1% in
PCI-32765–treated vs 32.5%± 7.3% in vehicle-treated tumors; Figure 3).
This was unexpected because pharmacological inhibition of mast cell
degranulation with cromoglycate does not elicit measurable inhibition
of tumor cell proliferation in the same tumor model [7].
PCI-32765 Does Not Compromise Glucose Tolerance
To ascertain whether the impact of PCI-32765 on β-cell tumors is a
trivial consequence of general toxicity to pancreatic β cells, we measured
physiological β-cell function in the presence and absence of compound.
Mice were fasted for 24 hours, challenged with a single i.p. bolus
of glucose, and blood glucose was then monitored thereafter every
20 minutes for 2 hours. Neither the efficiency nor the kinetics of
response to glucose challenge was adversely affected by treatment with
PCI-32765 (Figure 4). Moreover, sustained treatment (4 weeks) of
normal mice with PCI-32765 led to no discernible loss of pancreatic
β-cell function over time (data not shown). Hence, PCI-32765 has no
deleterious impact on normal pancreatic β-cell function or viability.
Sustained PCI-32765 Treatment Elicits Regression of
Multifocal Insulinomas
To model the impact of PCI-32765–based therapy on established
β-cell tumors, we mimicked the gastrointestinal route of PCI-32765
administration adopted in ongoing PCI-32765 clinical trials. PCI-
32765 was introduced into the drinking water to deliver a dose of
30 mg/kg per day. Ins-MycERTAM;RIP7-Bcl-xL mice were pretreated
for 2 weeks with tamoxifen to induce β-cell tumors, and PCI-32765
(or vehicle control) was then administered orally (together with daily
tamoxifen to maintain Myc activity) for a further 4 weeks. Using a
fluorescently tagged PCI-32765 derivative (PCI-33380 [8]), we ascer-
tained that this dose achieves complete Btk occupancy (Figure 5A). As
we expected, although systemic inhibition of Btk had no effect on re-
cruitment of mast cells to tumor stroma, it efficiently blocked their
degranulation (13% ± 2.1% degranulating cells in PCI-32765–treated
vs 87.2% ± 3.2% in vehicle-treated tumors; Figure 5B).
After 6 weeks of sustained Myc activation in non–PCI-32765–
treated Ins-MycERTAM;RIP7-Bcl-xL mice, β-cell tumors attain a size
(measured as area per section) that is 16.97 ± 4.3-fold that in normal
islets (Figure 6A). By contrast, 4 weeks of cotreatment with PCI-32765
elicited a dramatic regression of all, shrinking the tumors to a mere 2.08 ±
0.4-fold relative to untreated islets (Figure 6A). Importantly, such re-
gressed islet tumors remain phenotypically distinct from their normal
counterparts, exhibiting ragged margins indicative of extensive cell
turnover and remodeling. The regressed β-cell masses also exhibited a
degenerate and rudimentary vasculature compared with control tumors
not treated with PCI-32765 (Figure 6B). Blood vessels in the regressed
Figure 5. Oral administration of PCI-32765 achieves complete Btk occupancy and systemically blockades mast cell degranulation. (A)
Btk occupancy assay on splenocyte lysates derived from Ins-MycERTAM;RIP7-Bcl-xL mice treated with tamoxifen and either PCI-32765 or
vehicle control. The black arrow indicates band relative to Btk. A schematic of the assay is shown on the left. (B) Toluidine blue staining
of pancreatic stroma of Ins-MycERTAM;RIP7-Bcl-XL mice treated with tamoxifen only (left panels) or with both tamoxifen and PCI-32765
(right panels). The smaller panels on both sides show higher magnification of single mast cells.
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PCI-32765–treated tumors seldom reached the inner parts of the islets,
which frequently (∼18% of the total islets) exhibited voids and hem-
orrhage (Figure W2).
Discussion
We previously reported in a mouse model of Myc-driven pancreatic
β-cell tumorigenesis that tumor progression is causally linked, and
continuously dependent on, infiltration of mast cells [7]. In their
absence, Myc-driven β cells exhibit a transformed phenotype and
markedly elevated proliferation rates yet are unable to expand into
macroscopic tumors because of their inability to establish and main-
tain a microenvironment conducive to angiogenesis and macroscopic
tumor growth. Moreover, systemic inhibition of mast cells with so-
dium cromoglycate, an inhibitor of mast cell degranulation, triggered
Figure 6. Long-term treatment with PCI-32765 causes tumor regression. Tumor bearing mice (already treated with tamoxifen for 2 weeks)
were treated with PCI-32765 or vehicle control in combination with a daily tamoxifen injection for 4 weeks. (A) H&E staining of sections
of pancreata harvested from Ins-MycERTAM;RIP7-Bcl-xL mice treated with PCI-32765 only (i), with tamoxifen only (6 weeks in ii and 2 weeks
in iii) or both (iv). (B) Meca32 staining (red) and Hoechst nuclear counterstaining (blue) of the same sections as described in A.
1098 Btk Inhibition in Insulinoma Soucek et al. Neoplasia Vol. 13, No. 11, 2011
degeneration of tumor vasculature, tumor hypoxia, and partial tumor
regression [7]. Cromoglycate has very poor systemic bioavailability and
is impractical for systemic use. Nonetheless, the partial tumor regres-
sion it induced suggested that efficient pharmacological inhibition of
mast cell degranulation might be a therapeutically beneficial strategy
in treating insulinoma and, potentially, other pancreatic tumors. In-
deed, immunohistochemical analysis of human biopsies from patients
affected by insulinoma shows that mast cells significantly infiltrate both
tumors and tumor stromas (Figure 7). Intriguingly, recent observations
that elevated mast cell infiltration in human pancreatic ductal adeno-
carcinoma correlates tightly with higher tumor grade and worse prog-
nosis [14] intimate that mast cells may play an analogous causal role in
exocrine pancreatic neoplasia.
Mast cell degranulation is critically dependent on the activity of Btk
[15,16] for which a specific inhibitor, PCI-32765, has been optimized
for oral availability, potency, selectivity, low toxicity, and capacity to
sustain Btk inhibition in vivo [8,9]. PCI-32765 has been also recently
shown to be efficacious in animal models of arthritis, lupus, and B-cell
lymphoma [8] and is currently in clinical development for the treat-
ment of B-cell non–Hodgkin lymphoma owing to the critical role
Btk plays in B-cell receptor signal pathway. Given its ability to interfere
also with mast cell function and its excellent drug-like properties, we
tested the impact of PCI-32765 on growth and maintenance of insu-
linomas in our validated Ins-MycERTAM;RIP7-Bcl-xL preclinical mouse
model [4,6,7,17]. PCI-32765 triggered a dramatic regression of tumors
without affecting normal β-cell function or having any discernible
adverse impact on overall health of mice. As predicted for an inhibitor
of mast cell degranulation, PCI-32765 did not prevent recruitment of
mast cells to tumors but, instead, blocked their degranulation once
there. Intriguingly, PCI-32765 also inhibited proliferation of neoplastic
β cells, although the mechanism underlying this additional therapeutic
benefit is presently unclear.
Our data further support the emerging notion that mast cell inhi-
bition is a novel and practical strategy for the treatment of insulinoma
and potentially other pancreatic neoplastic diseases and suggests that
PCI-32765 is as an effective systemic mast cell inhibitor in clinical
assessment of this principle.
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Figure W2. Sustained PCI-32765 treatment induces necrotic lesions in β-cell tumors. H&E staining of sections from pancreata harvested
from Ins-MycERTAM;RIP7-Bcl-xL mice treated with tamoxifen plus PCI-32765. Arrows indicate regions within the islets where tissue ap-
pears damaged, with small blood pools or hemorrhage, consistent with lack of proper vasculature.
Figure W1. Myc drives insulinoma progression and expansion in the absence of mature B cells. H&E staining of sections of pancreata
harvested from RIP7-Bcl-xL;Ins-MycERTAM;RIP7-Bcl-xL and JH
−/−;Ins-MycERTAM;RIP7-Bcl-xL mice treated with tamoxifen for 2 weeks.
